Can You Take Cabotegravir with PNV 27-Ca/Fe/FA?

Food may reduce the absorption and blood levels of multivitamin, prenatal. In addition, some oral medications can also interfere with multivitamin, prenatal absorption into the bloodstream, which may make the medication less effective in treating your condition. Likewise, multivitamin, prenatal may interfere with the absorption of other orally administered medications. You should take multivitamin, prenatal on an empty stomach at least one hour before or two hours after a meal. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Talk to your doctor or pharmacist if you have questions about how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Depressive disorders (including depressed mood, depression, altered mood, mood swings) have been reported with oral cabotegravir. Depressive disorders (including depressed mood, depression, major depression, altered mood, mood swings, dysphoria, negative thoughts, suicidal ideation/attempt) have been reported with IM cabotegravir-rilpivirine or the individual drug products. Patients with severe depressive symptoms should be evaluated promptly. Caution should be used in patients with a history of depression or other psychiatric conditions.

Hepatotoxicity has been reported in patients taking cabotegravir with or without known preexisting hepatic disease or identifiable risk factors. Patients with underlying liver disease or marked transaminase elevations prior to therapy may be at increased risk for worsening or development of transaminase elevations. Monitoring of liver chemistries is recommended and cabotegravir should be discontinued if hepatotoxicity is suspected. Cabotegravir has not been studied in patients with severe liver dysfunction (Child-Pugh C); caution is recommended.

Depressive disorders (including depressed mood, depression, altered mood, mood swings) have been reported with oral cabotegravir. Depressive disorders (including depressed mood, depression, major depression, altered mood, mood swings, dysphoria, negative thoughts, suicidal ideation/attempt) have been reported with IM cabotegravir-rilpivirine or the individual drug products. Patients with severe depressive symptoms should be evaluated promptly. Caution should be used in patients with a history of depression or other psychiatric conditions.

No dose adjustment of IM or oral cabotegravir is required in patients with mild to moderate or mild to severe renal dysfunction, respectively. Cabotegravir has not been studied in patients with ESRD not on dialysis; caution is recommended. IM cabotegravir should be used with caution and with increased monitoring for side effects in patients with severe renal dysfunction or ESRD.